Thalys Medical Technology Group's core business segment revolves around the research, development, production, and sale of in vitro diagnostic (IVD) products. This segment focuses on creating innovative diagnostic solutions for various medical conditions. R&D efforts are directed towards developing novel diagnostic reagents and improving existing testing methodologies. The company leverages its expertise in biotechnology and clinical research to enhance the accuracy and efficiency of its IVD products. These products play a crucial role in disease detection, monitoring, and personalized treatment strategies, ultimately improving patient outcomes and healthcare delivery. Thalys Medical aims to expand its market share in the IVD sector through continuous innovation and strategic partnerships.